Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10301 - 10325 of 10619 in total
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
Investigational
Matched Description: … Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and …
Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).
Investigational
Matched Description: … investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
Experimental
Matched Description: … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated …
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … RPI-78M is being developed for the treatment of multiple sclerosis (MS). …
Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.
Experimental
Matched Description: … Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. …
Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.
Investigational
Matched Description: … Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma …
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research …
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
Matched Description: … which is manufactured in a way that retains the naturally occurring microRNAs without the addition of
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
Matched Description: … A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) …
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
Matched Description: … With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal …
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and …
Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected to block fat absorption with fewer side effects than currently marketed lipase...
Investigational
Matched Description: … GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of
RO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein. RO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And/or Metastatic Solid Tumors).
Investigational
Matched Description: … under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of
Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia. Oxogluric...
Experimental
Investigational
Nutraceutical
Matched Description: … decreased synthesis of muscle protein that is often seen post-surgery. ... in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of ... Several experimental studies have also shown that administration of oxogluric acid helped attenuate the …
DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Investigational
Matched Description: … DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA …
Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.
Investigational
Matched Description: … Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced …
Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome).
Investigational
Matched Description: … under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of
2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma, and Recurrent Mantle Cell Lymphoma, among others.
Investigational
Matched Description: … 2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine …
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). …
Red blood cell-encapsulated L-asparaginase is Asparaginase Escherichia coli encapsulated inside donor-derived red blood cells, which target cancer cells capable of altering asparagine and glutamine metabolism. It is being investigated in cancers.
Investigational
Matched Description: … Escherichia coli] encapsulated inside donor-derived red blood cells, which target cancer cells capable of
beta-Alanine is an amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
Experimental
Matched Description: … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine]. …
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of
AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational
Matched Description: … It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA …
A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.
Experimental
Matched Description: … (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. …
Displaying drugs 10301 - 10325 of 10619 in total